Trials / Completed
CompletedNCT05567159
A Study of Donanemab (LY3002813) in Healthy Participants
A Phase 1, Open-Label Study to Characterize the Pharmacokinetics of Donanemab Following Intravenous Doses in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to assess how fast donanemab (LY3002813) gets into the blood stream and how long it takes the body to remove it when administered as single dose in healthy participants. The study will also evaluate the safety and tolerability of donanemab. The study will last up to approximately 22 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Donanemab | Administered IV. |
Timeline
- Start date
- 2022-10-04
- Primary completion
- 2023-07-14
- Completion
- 2023-07-14
- First posted
- 2022-10-05
- Last updated
- 2024-10-04
- Results posted
- 2024-10-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05567159. Inclusion in this directory is not an endorsement.